Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

781.88 +26.88 (+3.56%)
Streaming Delayed Price Updated: 9:37 AM EST, Nov 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
99 100 Next >
New Weight Loss ETF Is Essentially A Play On Eli Lilly, Novo Nordisk
New OZEM ETF offers investors exposure to weight-loss sector through top pharmaceutical companies Eli Lilly and Novo Nordisk, with potential for high growth but also risks. 
Via Benzinga
Topics ETFs
Weight Loss Drug Market To Rocket To $130B By 2030 With Eli Lilly, Novo Nordisk In Lead: Goldman Sachs
Goldman Sachs re-rated Eli Lilly and Novo Nordisk, citing potential for weight-loss drugs. Global sales expected to reach $130B by 2030. 
Via Benzinga
Urban Outfitters, Eli Lilly And 2 Other Stocks Insiders Are Selling
Via Benzinga
Blue-Chip Bubble Trouble: 7 Stocks to Short as Valuations Stretch to the Limit
Be careful with these overvalued blue-chip stocks, each of which is trading at a high multiple relative to its peers. 
Via InvestorPlace
Nvidia Is Up 186% From A Year Ago, Yet These 7 Stocks Have More Than Doubled Their Returns Over The AI Chipmaker
NVIDIA Corp. (NASDAQ:NVDA) has been the standout tech stock of the past year, leading the Nasdaq 100 index in the performance ranking. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Could Eli Lilly Be the Next to Join the Trillion-Dollar Club?
Today, Eli Lilly's market value tops $700 billion. 
Via The Motley Fool
FDA Conditionally Approves Eli Lilly's Thyroid Cancer Drug For Pediatric Patients With Certain Mutations
Accelerated FDA approval for Eli Lilly's selpercatinib (Retevmo) in pediatric patients aged 2+ with advanced/metastatic thyroid cancer & solid tumors carrying RET mutations or fusions. 
Via Benzinga
Exposures Product Safety
3 Sorry Pharma Stocks to Sell in May While You Still Can
Discover three pharma stocks to sell in May while you still can. Avoid these companies facing significant setbacks. 
Via InvestorPlace
Jim Cramer Recommends Buying Apple, Finds This Tech Stock 'Very Interesting'
On CNBC's "Mad Money Lightning Round," Jim Cramer said Apple Inc. is a "buy" after iPhone sales in China saw a 52% year-on-year increase. 
Via Benzinga
If You Can Only Buy One Biotech Stock in May, It Better Be One of These 3 Names
Between FDA approvals and product pipelines, it takes diligence to keep up with which biotech stocks to buy. 
Via InvestorPlace
Exposures Product Safety
Weight-Loss Drug Forecasts Skyrocket To $150B As Novo Nordisk, Eli Lilly Ramp Up Supply
The global market for weight-loss drugs is expected to reach a staggering $150 billion by the early 2030s, a significant increase from the previous forecast of $100 billion. This surge is attributed to... 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Nvidia's Meteoric Rise: How Does It Compare To Other Market Rallies?
Bespoke analysts compared Nvidia to Microsoft, Amazon and Apple. Here's what the experts determined about the company's stock rally. 
Via Benzinga
A New Name in Weight Loss Drugs
Novo Nordisk and Eli Lilly have soared on the popularity of GLP-1 weight loss drugs. Now Hims & Hers is trying to get in on the action with a more available and affordable option. 
Via The Motley Fool
OZEM ETF: 7 Things to Know About the New Roundhill GLP-1 & Weight Loss ETF
As weight loss drugs are gaining popularity Roundhill GLP 1 And Weight Loss ETF (OZEM) has launched as anew way to invest in them. 
Via InvestorPlace
Topics ETFs
The Dividend Acceleration Squad: 3 Stocks With Rapidly Rising Yields
Dividend stocks that grow their returns faster than others are worth considering for investors interested in growing their incomes. 
Via InvestorPlace
LifeMD Can Surge on Its GLP-1 Offerings
LifeMD is a leading telehealth provider that investors should take note of; the company is entering the GLP-1 market, and its stock could soar as a result 
Via MarketBeat
Soaring Eli Lilly Stock Could Climb Another 24% According to a Wall Street Analyst. Is the Stock a Buy Now?
Plowing $9 billion into a manufacturing facility could help a successful tirzepatide launch reach new heights. 
Via The Motley Fool
'Not Just A Weight Loss Story:' Eli Lilly CEO Thinks It's Possible To Meet BofA's $60B Revenue Projection From New Drug Launches
Ricks highlighted that the company is trying to prove the efficacy of its drugs for not only weight loss but also obesity-driven diseases such as heart risks, diabetes, and sleep apnea. 
Via Benzinga
The Penny Stock Prophecy: 3 Overlooked Stocks Primed to Pop
Overlooked penny stocks are the path to outsized gains and these shares seem to fit the bill at the moment. 
Via InvestorPlace
10 Best Vanguard Funds to Buy Right Now
These 10 Vanguard stock ETFs can help you build a top-notch portfolio. 
Via The Motley Fool
Topics ETFs
Chinese Scientists Achieve World's First Diabetes Cure Using Cell Therapy: Report
A team of Chinese scientists has successfully cured a patient's diabetes using cell therapy, marking a global first. 
Via Benzinga
Got $500? 3 Pharma Stocks to Buy and Hold Forever
These players might even beat the market when the conditions are right. 
Via The Motley Fool
Amgen's Catching Up to Novo Nordisk and Eli Lilly. Should You Buy It?
The gold rush for obesity medications just got a bit more intense. 
Via The Motley Fool
3 High-Flying Stocks That Could Soar Even More
The momentum should continue for Eli Lilly, Novo Nordisk, and Vertex Pharmaceuticals. 
Via The Motley Fool
Elon Musk Says Ozempic 'Will Become Very Cheap' After New Comedy Special Paints It As Weight Loss Drug Only Wealthy People Can Afford
Elon Musk predicts that Novo Nordisk's weight-loss drug Ozempic will eventually become very cheap, following its depiction in a new South Park special as a luxury medication accessible only to the... 
Via Benzinga
Eli Lilly Makes Largest Manufacturing Investment In Its History To Boost Production For Antidiabetic And Weight Loss Meds
Eli Lilly has significantly increased its investment in its Lebanon, Indiana, manufacturing site to $9 billion, aiming to enhance production of tirzepatide injections. 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Stock Market Hits A Wall Despite Booming Nvidia: Weekly Review
The Nasdaq and S&P 500 hit record highs, but fell back. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Jim Cramer Says This Basic Materials Stock Is 'Too Dicey,' Shares His Take On Arista Networks
"All of these stocks are a little volatile right now, but I think you want to own it and buy it into the volatility," Jim Cramer says. 
Via Benzinga
< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.